Milanes-Guisado, YusnelkisGutierrez-Valencia, AliciaTrujillo-Rodriguez, MariaEspinosa, NuriaViciana, PompeyoLopez-Cortes, Luis Fernando2023-01-252023-01-252018-10-22Milanés-Guisado Y, Gutiérrez-Valencia A, Trujillo-Rodríguez M, Espinosa N, Viciana P, López-Cortés LF. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. PLoS One. 2018 Oct 22;13(10):e0205777.http://hdl.handle.net/10668/13116To analyse the correlation and concordance between aCD4, CD4%, CD4/CD8, their intra-patient variability, and to compare the immune recovery (IR) rates based on the three parameters in HIV-infected patients after starting antiretroviral therapy. From a prospectively followed cohort, patients who maintained HIV-RNA suppression in ≥95% of the determinations throughout the follow-up were selected. IR was defined as aCD4 >650/μl, CD4% ≥38% or CD4/CD8 ≥1. A total of 1164 patients with a median follow-up of 5 years were analysed. The increases in aCD4, CD4% and CD4/CD8 were highest during the first year and considerably lower thereafter regardless of baseline aCD4. The annual increases in aCD4 showed poor correlations with those of CD4% (r = 0.143-0.250) and CD4/CD8 (r = 0.101-0.192) but were high between CD4% and CD4/CD8 (r = 0.765-0.844; p650/μl, CD4% ≥38%, and CD4/CD8 ≥1, respectively, while only 31% achieved both aCD4 and CD4/CD8 target values. The increases in aCD4 poorly correlate with those of CD4% and CD4/CD8. IR rates based on aCD4 significantly overstate those obtained by CD4% and CD4/CD8. CD4% and CD4/CD8 are more stable markers than aCD4 and should be taken into account to monitor the IR after treatment initiation.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Anti-HIV AgentsCD4-CD8 RatioCohort StudiesHIV-1Middle AgedSustained Virologic ResponseYoung AdultAdultAgedBiological Variation, PopulationBiomarkersCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleFollow-Up StudiesHIV InfectionsHumansMaleProspective StudiesRetrospective StudiesViral Loadresearch article30346965open accessPacientesVIHSupresiónOrganización Mundial de la SaludTerapéuticaEstándares de referenciaCuidados posterioresARN10.1371/journal.pone.02057771932-6203PMC6197681https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0205777&type=printablehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197681/pdf